No Data
No Data
No Data
No Data
No Data
We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Needs To Drive Business Growth Carefully
Yahoo FinanceApr 15 18:03
Anebulo Pharmaceuticals: Strong Buy Rating Amid Promising Clinical Advances and Rapid FDA Track
TipRanksFeb 16 03:25
New Debt & Financing Risk for Anebulo Pharmaceuticals, Inc. – What's the Latest?
TipRanksFeb 15 14:02
Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug
The biopharmaceutical company Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) reported its second quarter financial results on Tuesday for the three months ended Dec. 31, 2023,The company's primary focus
BenzingaFeb 15 00:37
Anebulo Pharmaceuticals Announces Richie Cunningham As Chief Executive Officer
Anebulo Pharmaceuticals Announces Richie Cunningham As Chief Executive Officer
BenzingaFeb 14 05:44
Anebulo Pharmaceuticals Q2 EPS $(0.11) Misses $(0.10) Estimate
Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.10) by 10 percent. This is a 26.67 percent increase over losses
BenzingaFeb 14 05:43
No Data
No Data